For a long time, eosinophils were regarded as the central effector cells of asthma and were interpreted in the classical model as a direct damaging agent of the epithelium, as an amplifier of bronchial hyperresponsiveness and as the main driver of type 2-mediated airway inflammation. Scientific developments over the past two decades have differentiated, expanded and in some cases questioned this picture. Are eosinophils in fact primary culprits – or merely markers of more complex immunological patterns? A new Lancet publication sheds some light on this.
Autoren
- Tanja Schliebe
Publikation
- Asthma/COPD-Special
Related Topics
You May Also Like
- From symptom to diagnosis
Abdominal pain – internal hernias
- Artificial intelligence for COPD
A new era of personalized treatment
- Multiple sclerosis
Spirulina as adjuvant therapy? Reduction of cytokines and inflammation
- IBD and SARS-CoV-2
Vulnerable at the mercy of others
- Case Report
53-year-old female patient with palmoplantar keratoderma
- Incontinence
Fecal incontinence from the perspective of gastroenterology
- Diagnostics of respiratory viral infections
What is tested when and on whom?
- HER2-positive breast cancer